British Agency Supports Eli Lilly's Weight Loss Drug Mounjaro, Diverging From Restrictions on Rival Novo Nordisk's Wegovy
Portfolio Pulse from Vandana Singh
The UK's National Institute for Health and Care Excellence (NICE) has recommended Eli Lilly's weight-loss drug Mounjaro for certain patients with obesity, without imposing a time limit, unlike Novo Nordisk's rival drug Wegovy. This could lead to Mounjaro being offered by the NHS as an alternative to Wegovy.
June 05, 2024 | 4:21 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
NICE's recommendation of Eli Lilly's Mounjaro without a time limit, unlike the restriction on Novo Nordisk's Wegovy, could negatively impact Wegovy's market share and sales.
The lack of a time limit on Mounjaro and its potential adoption by the NHS could reduce the market share and sales of Wegovy, negatively impacting Novo Nordisk's stock.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 80
POSITIVE IMPACT
NICE's recommendation of Eli Lilly's Mounjaro for obesity without a time limit could lead to increased adoption and sales, especially if the NHS offers it as an alternative to Wegovy.
The recommendation by NICE without a time limit and the potential for NHS adoption could significantly boost Mounjaro's market share and sales, positively impacting Eli Lilly's stock.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100